HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Matthew Caufield has reiterated a 'Buy' rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a price target of $28.
August 11, 2023 | 11:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Phathom Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $28.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Phathom Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100